Mehmood Yasir, Shahid Hira, Ul Huq Umar Inzamam, Rafeeq Hamza, Khalid Hafiz Muhammad Bilal, Uddin Mohammad N, Kazi Mohsin
Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Government College University Faisalabad, Faisalabad P.O. Box 38000, Pakistan.
Riphah Institute of Pharmaceutical Sciences (RIPS), Riphah International University Faisalabad, Faisalabad P.O. Box 38000, Pakistan.
Gels. 2023 Nov 1;9(11):871. doi: 10.3390/gels9110871.
Tacrolimus (TL) is a topical calcineurin inhibitor immunosuppressive drug widely used to manage various skin disorders. Herein, we report a TL-loaded microsphere gel formulation with severe atopic dermatitis effects that are required to manage skin disorders. The current study adopted a modified emulsion solvent evaporation technique to synthesize TL-loaded microspheres, which were further converted into gels for skin use. Characterization of the synthesized formulation was performed by differential dynamic light scattering, scanning electron microscopy (SEM), Fourier transform infrared (FTIR) spectroscopy, X-ray crystallography, Brunauer-Emmett-Teller (BET) analysis, differential scanning calorimetry, and drug release. A Franz diffusion cell was used to study the diffusion of TL for up to 8 h at pH 6.8 and 5.5. Evaluation of cell viability was determined by MTT assay and showed higher IC50 values compared to the plain drug. RNA extraction, real-time polymerase chain reaction (RT-PCR), and reverse transcription were also performed to determine the expression levels of the anti-inflammatory cytokine IL-2. Particle size determination was performed by a zeta sizer, and the TL microsphere size was 1745 ± 70 nm with a good polydispersity (0.337 ± 0.12). The drug entrapment efficiency was also very good at 60% ± 10, and the drug release was 93.9% ± 3.5 within 8 h. An in vitro diffusion study of the formulation also showed improved permeability at both pH values (4.5 and 5.5). The findings of the hemolytic tests demonstrated that TL-MG at concentrations of 50, 100, and 200 mg/mL did not produce any hemolysis. A dose-dependent pattern of cytotoxicity was found during the cell viability assay, with an IC50 value of 787.55 ± 12.78 µg/mL. There was a significant decrease in the IL-2 level in the TL-MG group compared to the other groups. TL-MG microspheres were nontoxic carriers for tacrolimus delivery, with greater loading capacity, a significant release profile, and enhanced cellular uptake with improved permeability.
他克莫司(TL)是一种局部用钙调神经磷酸酶抑制剂免疫抑制药物,广泛用于治疗各种皮肤疾病。在此,我们报告一种具有严重特应性皮炎效应的载他克莫司微球凝胶制剂,用于治疗皮肤疾病。当前研究采用改良的乳液溶剂蒸发技术合成载他克莫司微球,然后将其进一步转化为用于皮肤的凝胶。通过动态光散射、扫描电子显微镜(SEM)、傅里叶变换红外(FTIR)光谱、X射线晶体学、布鲁诺尔-埃米特-泰勒(BET)分析、差示扫描量热法和药物释放对合成制剂进行表征。使用Franz扩散池研究他克莫司在pH 6.8和5.5条件下长达8小时的扩散情况。通过MTT法测定细胞活力,结果显示与普通药物相比具有更高的IC50值。还进行了RNA提取、实时聚合酶链反应(RT-PCR)和逆转录,以确定抗炎细胞因子IL-2的表达水平。通过粒度分析仪测定粒径,他克莫司微球粒径为1745±70 nm,具有良好的多分散性(0.337±0.12)。药物包封率也非常好,为60%±10,药物在8小时内释放率为93.9%±3.5。该制剂的体外扩散研究还表明在两个pH值(4.5和5.5)下通透性均有所提高。溶血试验结果表明,浓度为50、100和200 mg/mL的他克莫司-微球凝胶(TL-MG)未产生任何溶血现象。在细胞活力测定中发现细胞毒性呈剂量依赖性模式,IC50值为787.55±12.78 µg/mL。与其他组相比,TL-MG组中IL-2水平显著降低。TL-MG微球是用于他克莫司递送的无毒载体,具有更大的载药量、显著的释放特性以及增强的细胞摄取和改善的通透性。